Breast Cancer Diagnostics: Start-Ups Look To Fill Gaps In The Patient Care Continuum
This article was originally published in Start Up
Mammography is a mature and successful breast cancer diagnostic technology, but it has many drawbacks, including high false-negative and false-positive rates, the use of ionizing radiation, and ineffectiveness in dense or scarred breast tissue. Emerging companies aim to improve on this gold standard as well as streamline radiological workflow and predict disease aggressiveness and recurrence. START-UP profiles four such companies in this issue: Delphinus Medical Technologies, Ibris, NovaScan and Real Time Tomography.
You may also be interested in...
Paige’s AI has obtained CE-IVD and UKCA marks, allowing the launch of a breakthrough product that can spot biomarkers from images.
The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.
The European Medicines Agency’s human medicines committee, the CHMP, is expected to decide whether 11 drugs should be recommended for marketing approval during its latest monthly meeting, which started today.